Eric Olson

Eric Olson is a Scientific Advisor at Tenaya Therapeutics. Eric has over 25 years of experience in the biotech industry, including positions at Celgene and Juno Therapeutics.

At Celgene, Eric led a team of computational biologists supporting translational and early discovery scientists in the Immuno-oncology/Cellular Therapy Thematic Center of Excellence (IO/CT TCoE). In addition to Cellular Therapy, the group's responsibilities expanded to include identifying targets for combination therapies with checkpoint inhibitors and targets for T-cell engagers in solid tumors. Eric was also a member of the Low Molecular Weight and Biotherapeutics target teams and Solid Tumor and B-cell Malignancy Research Strategy Teams (co-lead ST RST).

At Juno Therapeutics, Eric conducted collaborative research with clinical, translational and basic science groups to increase understanding of disease-associated biological processes and responses to immunotherapies. Eric also led efforts to identify and characterize novel cellular therapy targets, including CAR T-cells and eTCR, and put in place a data mining and target scoring process as well as a pipeline for characterization of target expression using IHC and ISH.

Eric has a PhD in Biology from Stanford University.

Eric Olson has a PhD in Pathology from the University of Washington - School of Medicine. Eric also has a Bachelor of Science in Molecular Biology from the University of Washington.